Saiontz & Kirk is no longer accepting new clients for Pradaxa Lawsuits
The contents of this page are provided for informational purposes only

Until May 2014, the product liability lawyers at Saiontz & Kirk, P.A. were reviewing potential lawsuits for individuals who have experienced severe internal bleeding on Pradaxa, a blood thinner that has been associated with reports of serious and life-threatening problems. Following a Pradaxa settlement reached to resolve all pending cases, new clients are no longer being accepted. This page is provided for informational purposes only.

Within the first year on the market, there were more than 260 Pradaxa deaths from internal bleeding experienced worldwide and it appears that the manufacturer failed to provide adequate warnings about the risk of Pradaxa bleeding side effects. Studies have also suggested their may be an increased risk of heart attacks from Pradaxa.

Compensation was pursued through a Pradaxa lawsuit for individuals who experienced:

  • Internal Bleeding or Gastrointestinal Bleeding
  • Brain Hemorrhage
  • Kidney Bleeding
  • Death

The Pradaxa lawyers at Saiontz & Kirk, P.A. are no longer pursuing potential claims in connection with this medication. However, Xarelto lawsuits are still being evaluated for the similar anticoagulant.


Pradaxa (dabigatran) was introduced by Boehringer Ingelheim on October 19, 2010 as a revolutionary blood thinner for prevention of strokes among patients suffering from atrial fibrillation. However, the medication has also been widely used off-label for purposes not approved as safe or effective by the FDA.

While all blood thinners carry a risk of gastrointestinal bleeding, reports suggested that Pradaxa carries a greater risk than was indicated on the warning label.

During the first three months the blood thinner was on the market in the U.S., the FDA received 307 reports of Pradaxa problems involving internal bleeding and other complications, particularly among elderly users.

According to a report by the Institute for Safe Medication Practices, which analyzed adverse event reports submitted to the FDA between October 2010 and December 2010, more problems with Pradaxa were reported than were associated 98.7% of the other drugs the organization monitors.

As of October 31, 2011, more than 260 deaths from Pradaxa internal bleeding problems worldwide were disclosed by Boehringer Ingelheim


Many critics have questioned the clinical trials used to gain FDA approval and some have suggested that a Pradaxa recall should be considered to protect consumers. Pradaxa was approved based on a clinical study known as RE-LY, which compared Pradaxa with warfarin, a blood thinner that has been on the market for decades. However, experts have indicated the study was fundamentally flawed, allowing bias and errors to creep into the results.

Individuals throughout the United States who experienced problems may be eligible to pursue a Pradaxa bleeding lawsuit as a result of Boehringer Ingelheim’s failure to adequately research their medication or warn about the risk of serious and potentially life-threatening side effects of Pradaxa.

Pradaxa was introduced as a blood thinner that was superior to warfarin because it requires less monitoring. However, users of warfarin who experience abnormal bleeding can coutneract those side effects with Vitamin K and there is no similar solution available to address Pradaxa bleeding, which may pose a more serious risk of users of the medication.


The attorneys at Saiontz & Kirk, P.A. are no longer reviewing potential Pradaxa class action lawsuits and individual injury lawsuits for individuals throughout the United States.

All Pradaxa cases were investigated under a contingency fee agreement, which means that there were no out-of-pocket expenses to hire our law firm and we receive no attorney fees until a recovery is obtained for a Pradaxa injury.